Malignant neoplasm of endometrium
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry (IHC) for the DNA MMR proteins MLH1, MSH2, MSH6, and PMS2 was performed on a tissue microarray of specimens of primary endometrial cancer.
|
20153885 |
2010 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lynch syndrome is caused by germline mutations in MSH2, MLH1, MSH6, and PMS2 mismatch-repair genes and leads to a high risk of colorectal and endometrial cancer.
|
21145788 |
2011 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We estimated the association between BMI at age 18-20 years and endometrial cancer risk for mismatch repair gene mutation carriers and, as a comparison group, noncarriers using 601 female carriers of a germline mutation in a mismatch repair gene (245 MLH1, 299 MSH2, 38 MSH6, and 19 PMS2) and 533 female noncarriers from the Colon Cancer Family Registry using a weighted Cox proportional hazards regression.
|
21422863 |
2011 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The Lynch syndrome (LS) is an inherited cancer syndrome showing a preponderance of colorectal cancer (CRC) in context with endometrial cancer and several other extracolonic cancers, which is due to pathogenic mutations in the mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and PMS2.
|
21769135 |
2011 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lynch syndrome is caused by germline mutations in MSH2, MLH1, MSH6, and PMS2 mismatch repair genes and leads to a high risk of colorectal and endometrial cancer.
|
21791569 |
2011 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lynch syndrome, which is associated with mutations in 1 of 4 mismatch repair genes (MLH1, MSH2, MSH6, and PMS2), is a well-described hereditary cancer predisposition syndrome associated with a substantial risk of colon, rectum, and endometrial cancer.
|
22846734 |
2013 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We obtained data from the Colon Cancer Family Registry for a cohort of 127 women who had a diagnosis of endometrial cancer and who carried a mutation in one of four MMR genes (30 carried a mutation in MLH1, 72 in MSH2, 22 in MSH6, and 3 in PMS2).
|
23385444 |
2013 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aims of this study were to define the prevalence and associations of deficient mismatch repair (dMMR) protein expression (MLH1, MSH2, MSH6, PMS2) by immunohistochemistry in a multiethnic Southeast Asian cohort with endometrioid endometrial cancer.
|
25272293 |
2014 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lynch syndrome (LS), a heritable disorder with an increased risk of primarily colorectal cancer (CRC) and endometrial cancer (EC), can be caused by mutations in the PMS2 gene.
|
26110232 |
2016 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
We suggest that MLH1 promoter methylation analysis for IL-PMS2 EC should be performed to exclude sporadic cases before further PMS2 genetic testing.
|
26848797 |
2016 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe a patient with a clinical diagnosis of CMMRD based on colorectal polyposis and young-onset endometrial cancer who was identified to have two alterations in trans in PMS2: one known pathogenic mutation (c.1831insA; p.Ile611Asnfs*2) and one novel variant of uncertain significance (c.505C>G; p.Arg169Glu), a missense alteration.
|
27017610 |
2016 |
Malignant neoplasm of endometrium
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In 2015, our institution implemented universal screening of endometrial cancer (EC) hysterectomy specimens by mismatch repair immunohistochemistry (IHC) with reflex MLH1 promoter hypermethylation analysis for tumors with loss of MLH1/PMS2 expression.
|
29107668 |
2017 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The PMS2 mutation was identified in a 57-year-old woman with a sebaceous adenoma and history of endometrial cancer; to our knowledge, this is the first time a PMS2 mutation has been reported in MTS.
|
29333623 |
2018 |
Malignant neoplasm of endometrium
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
When losses of both MLH1 and PMS2 proteins are observed by IHC, MLH1 promoter methylation analysis is conducted to distinguish Lynch syndrome-associated endometrial cancer from sporadic cancer.
|
29783979 |
2018 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
LS is caused by heterozygous germline variants of MSH2, MSH6, PMS2 and MLH1 and characterized by an increased risk of developing colorectal and endometrial cancer at adult age.
|
29904176 |
2018 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer.
|
30161022 |
2018 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lynch syndrome is a cancer-predisposing syndrome inherited in an autosomal-dominant manner, wherein colon cancer and endometrial cancer develop frequently in the family, it results from a loss-of-function mutation in one of four different genes (MLH1, MSH2, MSH6, and PMS2) encoding mismatch repair proteins.
|
31273487 |
2019 |